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Abstract 
Veno-arterial extracorporeal membrane oxygenation (V-A ECMO) is established therapy for short-
term circulatory support for children with life-treating cardiorespiratory dysfunction. In children with 
congenital heart disease (CHD), ECMO is commonly used to support patients with post-cardiotomy shock or 
complications including intractable arrhythmias, cardiac arrest, and acute respiratory failure. Cannulation 
configurations include central, when the right atrium and aorta are utilized in patients with recent 
sternotomy, or peripheral, when cannulation of the neck or femoral vessels are used in nonoperative 
patients. ECMO can be used to support any form of cardiac disease including univentricular palliated 
circulation. Although V-A ECMO is commonly used to support children with CHD, veno-venous ECMO (V-V 
ECMO) has been used in selected patients with hypoxemia or ventilatory failure in the presence of good 
cardiac function. ECMO use and outcomes in the CHD population are mainly informed by single-center 
studies and reports from collated registry data. Significant knowledge gaps remain, including optimal 
patient selection, timing of ECMO deployment, duration of support, anticoagulation, complications, and the 
impact of these factors on short- and long-term outcomes.  This report, therefore, aims to present a 
comprehensive overview of the available literature informing patient selection, ECMO management, and 































Mechanical circulatory support (MCS) is well-established therapy for children with severe refractory 
pulmonary or cardiac failure.1 In the 1970s, the first use of extracorporeal circulatory support in infants 
with congenital heart disease (CHD) was reported, followed by a longer extracorporeal membrane 
oxygenation (ECMO) run after surgical correction of Tetralogy of Fallot (TOF). 2,3 Despite the availability of 
other modes of support, including ventricular assist devices, ECMO remains the most commonly used form 
of MCS in the pediatric population.4 In January 2019 the Extracorporeal Life Support Organization (ELSO) 
Registry reported 19,629 cardiac ECMO cases in neonates and children from 350 international centers 
between 1990 and 2019 (https://www.elso.org/Registry/Statistics/International Summary.aspx). According 
to the ELSO registry, hypoplastic left heart syndrome (HLHS) was the most common CHD diagnosis for 
neonates supported with ECMO, and cyanotic CHD with decreased pulmonary flow (e.g. TOF, double outlet 
right ventricle, and Ebstein’s anomaly of the tricuspid valve) were the most common CHD diagnoses 
associated with cardiac ECMO in children.  
Veno-Arterial ECMO (V-A ECMO) is utilized in children with cardiac failure after CHD surgery, in 
order to augment cardiac output and facilitate respiratory gas exchange. Indications for V-A ECMO in this 
population include failure to wean from cardiopulmonary bypass (CPB), thrombosis of systemic-to-
pulmonary artery shunts in patients with palliated single ventricle circulation, intractable arrhythmias, 
postoperative low cardiac output syndrome, and cardiac arrest.1 Post-cardiotomy ECMO (PC-ECMO) may 
additionally bridge patients to myocardial recovery, or provide temporary MCS support as a bridge to 
cardiac transplantation or durable MCS.8,9, 10 V-A ECMO has also been described as bridge to CHD surgery in 
the setting of profound cyanosis, cardiogenic shock or pre-operative cardiopulmonary arrest (CPA).5,6,7  
The use of ECMO to support children following CHD surgery has increased steadily during the past 3 
decades.11-15 This increased use reflects growing experience with repair or palliation of complex forms of 














of ECMO management. Furthermore, advances in ECMO pump and oxygenator design, reduction of blood-
prosthetic surface interaction with coated ECMO circuit tubing, and improved anticoagulation protocols 
have resulted in increased ECMO use.16 Despite increasing experience and improved ECMO technology, 
mortality in pediatric patients requiring ECMO support following CHD surgery is high and has remained 
unchanged over the last several decades.12 
We aimed to summarize the current literature regarding PC-ECMO in pediatric patients with CHD. 
We provide a detailed and comprehensive summary of patient characteristics, ECMO management and 
complications, and short- and long-term outcomes of these patients. Future perspectives including novel 
indications, targets for clinical education, ethical considerations and optimal resource use will be 
highlighted. 
 
Characteristics of PC-ECMO 
Trends in ECMO use 
Utilization of PC-ECMO is variable among institutions performing surgery for CHD. Differences in 
ECMO utilization may reflect variation in technical performance, chosen operative interventions as well as 
ECMO availability, local indications for use, and the cost of ECMO. Prior to 1990, several authors reported 
that 1.5 -13% of children who underwent cardiac surgery for CHD were supported with ECMO (Table 1).13, 
17-19 Using data from the Pediatric Health Information System, which contains administrative data from 42 
children’s hospitals in the United States, Bratton and colleagues reported that from 2003-2014, 0.5% to 6% 
of children who underwent cardiac surgery for CHD were supported with ECMO.20 A recent analysis using 
the Society of Thoracic Surgeons (STS) Congenital Heart Surgery Database identified 2287 children (2.4%) 
supported postoperatively with MCS from the 96,596 operations performed for CHD from 2000-2010.21 
Most were supported with ECMO (>95%). The report showed ECMO was most commonly used in children 














repairs (14%). The findings illustrated the wide variability in ECMO utilization across the CHD centers 
reporting to the STS database. 
Patient characteristics  
ECMO has been successfully deployed to support children of all ages, from newborn to adult-sized 
patients with CHD requiring cardiac surgery.16, 18, 22-24 Similarly, PC-ECMO support has been utilized in 
children of all sizes, although the small vessels in premature and low birthweight infants can make the 
placement of appropriately sized ECMO cannula challenging. PC-ECMO has been used to rescue children 
after surgery for all forms of CHD, although it is more frequently used to support children undergoing more 
complex procedures (Table 1).23, 25-27  
Indications for ECMO 
The indications for and rates of ECMO implantation in pediatric patients vary among different 
studies; however, common indications include failure to wean from CPB, cardiac arrest, low cardiac output 
syndrome or respiratory failure (Table 2). Klein and colleagues reported pathophysiology resulting in ECMO 
support included biventricular failure (36%), right ventricular failure (14%), left ventricular failure (33%), 
and pulmonary hypertensive crisis (17%).17 Some populations are particularly high risk, for example, in a 
study of single ventricle patients palliated with systemic-to-pulmonary artery shunts, nearly half of 27 
patients required ECMO implantation. 28 And other studies appear to represent different population, for 
example, in two studies of PC-ECMO in children, low cardiac output as an indication for ECMO was present 
in 17% of 93 patients, and 92% of 73 patients.29, 23 Cardiac or cardiopulmonary arrest occurred in 6%, or 
28% of the respective populations. Pulmonary arterial hypertension, arrythmia and failure to wean from 
CPB are also represented in different proportions (Table 2).   














ECMO cannulation strategy is determined by underlying the anatomy and physiology of CHD. An 
analysis of all pediatric patients (0-18 years old) reported to the ELSO Registry demonstrated carotid 
cannulation in 64% of patients, aortic cannulation in 32%, and femoral cannulation in only 4%.30 In many 
centers, central cannulation of the right atrium for venous drainage and aorta for arterial return is 
commonly used in the presence of a recent sternotomy (Figures 1-3). In many circumstances, peripheral 
vessel cannulation may be the preferred approach to reduce the risk of major bleeding and infections1. 
Vascular access for peripheral V-A ECMO cannulation can be achieved through the neck vessels (internal 
jugular vein and carotid artery) or through the femoral vessels (femoral vein and artery) in children 
weighing >15 kg. Children with single ventricle circulation palliated with cavopulmonary connections 
(bidirectional Glenn and Fontan circulations) frequently need multisite cannulation for venous drainage. In 
rare instance when patients have adequate cardiac function and only require lung support, veno-venous 
ECMO (V-V ECMO) can be used, and the cannulas for drainage and return are both placed in the venous 
circulation. 
 Children with complex congenital heart defects are at risk for occlusion of peripheral vessels used 
for ECMO cannulation, because the vessels may have been accessed previously for cardiac catheterization. 
Thus, knowledge of vessel patency is important in children with complex CHD and previous history of 
multiple cardiac catheterization procedures. Chan and colleagues, in a report of 492 children with CHD 
supported with ECMO following cardiac arrest, showed that the use of the right carotid artery for V-A 
ECMO was associated with improved survival to hospital discharge as compared with transthoracic 
cannulation. The authors speculate that the reason for improved survival may be related to fewer 
cardiopulmonary resuscitation (CPR) interruptions during neck cannulation.31  Finally, the American Heart 
Association recently published a statement on cardiopulmonary resuscitation in children with CHD, which 
















Survival and duration of ECMO support  
After PC-ECMO, survival-to-hospital-discharge ranges from 40-60% in most studies of pediatric 
patients. (Table 3). Many factors influence the duration of PC-ECMO support in children, including the 
underlying cardiac lesion, presence of residual lesion, the family’s wishes, cardiac surgical recovery time, 
and the applicability of bridging to transplant if recovery does not occur. Thus, the number of hours of PC-
ECMO support varies greatly among different studies, ranging from 17 to more than 200 hours (Table 3).17, 
19 Survival to ECMO decannulation and hospital discharge also varies in the reported literature, with 
between 49 to 58% making it home alive.17,19,33 These mainly single center studies report higher survival 
than typically found in ELSO registry reports of the pediatric cardiac population.12 Longer-term survival, for 
example at 1 year post PC-ECMO has been reported as high as 41% (Table 3). 33 
Survival to hospital discharge may also vary by age and weight, with higher risk of death in 
neonates. 16, 18, 22-24 Infants weighing <3 kg have been reported to have high risk of death after ECMO 
support.35-37 In a study of 4,471pediatric patients supported with ECMO for cardiac indications reported to 
the ELSO registry, there were no survivors among 9 patients weighing < 1.5 kg, and survival was 25% among 
those who weighed 1.5 – 2 kg.36 In premature infants, immaturity of the choroid plexus may result in the 
higher incidence of intracranial hemorrhage. Birthweight < 3 kg has been associated with increased risk of 
neurological complications in PC-ECMO for CHD. 38 Indeed, both prematurity and lower birthweight were 
associated with increased mortality and a higher incidence of neurological complications in a study of 641 
neonates supported with ECMO following cardiac arrest by McMullan and colleagues.39 Bhat and 
colleagues also examined PC-ECMO used in infants weighing 3 kg or less; 52% of the patients were 
decannulated from ECMO and 28.1% survived until discharge.35 This study reported one of the longest 














to provide adequate ECMO support is affected by size, and neurological complications may limit survival in 
premature neonates (< 34 weeks gestation or birthweight < 2 kg). 
Survival to hospital discharge also varies widely based on the complexity of the underlying cardiac 
surgical procedure.25, 27, 33, 40 Allan and colleagues compared the indications for initiation of ECMO in infants 
with shunted single-ventricle physiology to the survival; 81% of patients cannulated for hypoxemia, but 
only 29% of those cannulated for hypotension survived to hospital discharge.41 Patients cannulated for 
shunt obstruction had the highest survival (83%). In an STS Congenital Heart Surgery Database study of 
2287 children supported postoperatively with MCS by Mascio and colleagues21, in-hospital mortality was 
highest among in patients supported after repair of truncus arteriosus, the Norwood single ventricle 
palliation operation for HLHS, or the Ross-Konno operation for repair of left ventricular outflow tract 
obstruction. In these circumstances, poor outcomes may be due to the accidental damage of the coronaries 
during surgery, serious aortic regurgitation after an incomplete repair, or an inherently poor systemic 
ventricle due to congenital aortic stenosis. Patients undergoing repair of an anomalous coronary artery 
from the left pulmonary artery had the best survival.21  
Predictors of mortality 
Many studies have identified similar predictors of in-hospital mortality, summarized by Walters and 
colleagues to include longer CPB time, the inability to separate from CPB, elevated blood nitrogen urea 48 
hours after ECMO cannulation, elevated creatinine 48 hours after ECMO cannulation, the need for red 
blood cells or plasma, and elevated right atrial pressure 8 hours after ECMO decannulation (Table 3).29 
Kolovos and colleagues18 found that CPR during ECMO cannulation, renal failure/dialysis, single ventricle 
palliated circulation, and a lactate trend within 48 hours of ECMO initiation to be associated with in-
hospital mortality. Alsoufi and colleagues42, 43 found that duration of ECMO, repeat ECMO, neurological 
complications, renal dysfunction, and mechanical complications were associated with in-hospital mortality. 














> 231 hours were predictors of poor prognosis.35 Renal failure is commonly associated with poorer 
prognosis in pediatric patients receiving PC-ECMO, which is in line with studies conducted in adults.44 Of 
note, continuous renal replacement therapy (CRRT) before ECMO is associated with worse outcomes than 
either no CRRT or CRRT started after ECMO. The former is indicative of underlying renal disease, while the 
latter may reflect an attempt to prevent fluid overload.45 Additionally, worse outcomes may be expected in 
patients with palliated single ventricle circulation with  Glenn or Fontan operations, due to the 
ineffectiveness of conventional CPR and the high risk of brain injury unless the bidirectional cavopulmonary 
connection is cannulated along with the inferior vena cava (ie. bicaval or central cannulation may be 
required).36,46 
ECMO for extracorporeal cardiopulmonary resuscitation 
Extracorporeal cardiopulmonary resuscitation (ECPR), or ECMO to support CPA, is an important and 
increasing use of ECMO in children who undergo cardiac surgery. Nonetheless, early institution of ECMO 
support prior to CPA in children with deteriorating hemodynamics in the postoperative period is preferable. 
In a study of 81 children supported with ECMO following cardiac surgery for CHD, Chaturvedi and 
colleagues reported that patients who underwent ECMO deployment in the operating room had improved 
survival to hospital discharge as compared with patients with ECMO was deployed in the intensive care unit 
(64% vs. 29%) suggesting that early institution of ECMO prevented exposure to a prolonged period of low 
cardiac output. 33  
The ELSO International Summary, January 2019 shows similar survival to discharge for neonates 
supported with ECMO for ECPR as compared with ECMO support for other cardiac indications (41% vs. 
42%), but lower survival to discharge for pediatric ECPR (42%) as compared to ECMO for other cardiac 
indications (52%) once the neonatal period is complete. Other studies have reported similar survival for 














with ECPR.48, 49 Survival-to-discharge for both ECPR and non-ECPR ECMO patients is heavily influenced by 
the ability to reverse the postoperative cardiorespiratory failure that necessitated ECMO support.  
 
Complications of Post-Cardiotomy ECMO in Pediatric Patients 
Important complications of PC-ECMO in children and neonates include bleeding, mechanical 
complications, liver failure, sepsis, central nervous system events, and renal failure which are reported at 
different rates in various studies (Table 4).17, 50, 33 Mechanical complications of ECMO are also common. 33 
Neurological sequalae occur frequently in children supported with ECMO. In a study of 90 patients 
by Chow and colleagues,51 only 15 children survived without neurological sequelae. There were short-term 
neurological events (22%) and long-term neurological sequelae (12%), accounting for 39% of survivors. In a 
study of 1,898 neonates with CHD reported to the ELSO Registry, 14% suffered a neurological injury.38 Risk 
factors for neurological injury included birth weight <3kg, pH <7.15 pre-ECMO, and the need for CPR prior 
to ECMO. Importantly, the patients who suffered neurological injury had higher in-hospital mortality (73%) 
as compared with those without neurological complications (53%). Khan and colleagues52 reported that 
17.5% of neonates supported on ECMO had intraventricular hemorrhage detected by cranial ultrasound 
(CUS). The investigators performed routine daily CUS on all neonatal patients and found that almost all 
intracranial hemorrhages occurred in the first 5 days after surgery (including pre-ECMO), and any 
hemorrhage after that time was associated with clinical symptoms. In infants with an open fontanelle, CUS 
is a safe bedside screening tool, which can be performed regularly when increased vigilance for 
neurological complications after ECMO cannulation is warranted.  
Although femoral cannulation is less common than carotid cannulation in pediatric patients, when 
the femoral approach is used, limb ischemia may be a serious complication.53 Methods to prevent limb 
ischemia in this setting include the use of contralateral femoral vessels for arterial and venous cannulation, 














use of a distal reperfusion cannula in an antegrade manner in the femoral artery or in a retrograde manner 
in the dorsalis pedis artery. In a single-center study of 29 children with femoral cannulation for V-A ECMO, 
Schad and colleagues54 found that 29% of those without routine distal perfusion catheter placement 
suffered ischemic complications, compared with only 12% when distal perfusion catheters were routinely 
placed. In addition, non-invasive limb perfusion monitoring with near infrared spectroscopy has translated 
to better outcomes.55 
 
Post-Cardiotomy Veno-Venous ECMO for Respiratory Dysfunction in Pediatric Patients 
Despite advances in CPB techniques and in preventive measures aimed at decreasing respiratory 
complications after cardiac surgery, postoperative acute respiratory distress syndrome (ARDS) occurs in 
1−20% of patients, depending on inclusion criteria. 56-59 The use of V-A ECMO for refractory cardiovascular 
dysfunction after pediatric cardiac surgery has been described, but there is paucity of data on the use of 
postcardiotomy V-V ECMO. Respiratory distress and hypoxia are reported as indications for ECMO support 
in 2-30% of pediatric patients.11, 13-15 V-V ECMO is an uncommon mode of support for patients with 
underlying cardiac disease, however in selected patients, it may be the mode of choice to facilitate 
oxygenation and decrease pulmonary vascular resistance.13   
 
Controversial Issues and Future Perspectives 
Cardiac catherization during PC-ECMO 
Diagnostic or therapeutic cardiac catheterization can be safely performed on patients receiving 
ECMO support.60 Early detection and correction of residual cardiac lesions is associated with improved 
survival.16,61 Catheter-based diagnostic procedures should be considered when non-invasive diagnostic 














left side of the heart.62 Callahan and colleagues reported the results of cardiac catheterization on 36 
pediatric patients supported by ECMO. 61 They found that the catheterization investigation excluded a 
residual lesion in 18% of the patients, confirmed a residual lesion in 15%, and identified unexpected 
residual cardiac lesions in 52%. Interventions to manage the residual lesion were performed in 50% of 
cases, including stenting, device closure, or thrombolysis. After the cardiac catheterization procedure, 86% 
of patients were weaned from ECMO and 72% survived to discharge. Of note, catheter-based diagnostic 
procedures performed during the first or second day of ECMO support (day 0 or 1) significantly reduced the 
duration of ECMO without impacting survival. Recently, Another single center report of cardiac 
catheterization on 51 children on  ECMO support demonstrated a low rate of serious complications (5.6%), 
and subsequent decannulation/weaning and survival rates were 71% and 54%, respectively. 63  These 
studies demonstrate the benefit of cardiac catheterization in evaluating PC-ECMO-supported patient, 
despite the complexity of interpreting hemodynamic measurements with ECMO cannulae in situ, with or 
without cessation of ECMO flow for the procedure. Transport of the ECMO patient for cardiac 
catheterization was reported as uncomplicated, and overall, the complication rate was low.61, 63 
Decompression of the left side of the heart 
Assessment and management of left heart decompression is a common indication for cardiac 
catheterization.61, 63 Left heart hypertension of patients managed on ECMO can be addressed by atrial 
septostomy, use of an axial trans-aortic valve pump (Impella), direct left ventricular venting via an open 
approach, or with left atrial cannulation, either directly or via catheter crossing the atrial septum. Eastaugh 
and colleagues reported percutaneous left heart decompression in 44 of 419 patients managed on V-A 
ECMO, via atrial septostomy, stenting of the atrial septum or left atrial venting across the atrial septum.64 
All techniques were equally successful at reducing left atrial pressure and decreasing pulmonary edema. 
Another single center study reported left heart decompression in 49 children managed on central V-A 
ECMO with left atrial venting, atrial septostomy, and left ventricle cannulation.65 Elective left heart 














improved survival. Recently, an Impella device was used to decompress the left ventricle of 4 children on V-
A ECMO.66 The device reduced left atrial pressure and increased tissue perfusion as observed by near 
infrared spectroscopy. Institutional preferences for assessment, timing, and mechanism of left heart 
decompression vary. 
Single ventricle physiology 
Despite advances in care, mortality after ECMO support in patients with single ventricle palliated 
circulation remains greater than 50%.18,67,28 The higher mortality in this subset of patients with cardiac 
palliation has been hypothesized as an imbalance between systemic and pulmonary blood flow and 
associated suboptimal coronary perfusion and increased probability of ventricular distension.28, 68 
Indications for ECMO in pediatric patients with single ventricle palliated circulation are comparable to those 
in patients with biventricular circulation, but additional complications are associated with systemic-to-
pulmonary artery shunts.62 When the pulmonary circulation is supplied by a systemic-to-pulmonary artery 
shunt and ECMO support is instituted, the shunt is most often left open. Adequate support of this 
circulation may require an augmented circuit blood flow of 150-200 ml/Kg/min to allow for diastolic run-off 
to the pulmonary circulation. In patients with single ventricle palliated circulation, cannulation strategy is 
an important issue.32, 41, 48 In-hospital mortality rates with the use of ECMO after the Norwood single 
ventricle palliation procedure exceed 50%.69, 70 ECMO support of patients with Glenn and Fontan circulation 
is associated with additional complexity due to the surgical anatomy and resulting physiology. Multiple 
drainage cannulae may be required to optimize support.32 In all stages of single-ventricle palliation, long-
duration ECMO, inotropic support, and renal failure are associated with higher mortality.48,49 The adequacy 
of the cannulation strategy should be questioned if the ECMO-supported patient with a single ventricle 















Against the background of high mortality prior to hospital discharge, the cost of ECMO support requires 
some consideration. Mahle and colleagues focused on hospital costs in 32 pediatric patients with CHD who 
received salvage ECMO (18 for cardiopulmonary arrest and 14 PC shock).71 Survival to hospital discharge 
was 50% and 1-year survival was 47%. The quality-of-life of the survivors was determined with the Health 
Utilities Index Mark II, and  median cost for hospital stay after institution of ECMO was $156,324 per 
patient. The calculated cost-utility for salvage ECMO in this population was $24,386 per quality-adjusted 
life-year saved, which would be considered within the range of accepted cost-efficacy (<$50,000 per 
quality-adjusted life-year saved). The authors note, however, that although the hospital costs for salvage 
cardiac ECMO are similar to those for neonatal ECMO for noncardiac indications, the calculated cost-utility 
is slightly less favorable. Salvage cardiac ECMO may be somewhat less cost-effective than noncardiac ECMO 
since the survival to hospital discharge is lower for cardiac patients. In addition, life expectancy for children 
with complex CHD, such as those with single ventricle palliated circulation, is lower than for children with 
respiratory distress in the neonatal period. Other investigators also noted a greater cost was associated 
with smaller hospitals and hospital location.72 
Bridging to heart transplantation 
ECMO support for children with circulatory failure awaiting heart transplantation has been 
analyzed using combined data from the ELSO Registry and the United States Organ Procurement Transplant 
Network (OPTN).10 The authors demonstrated that ECMO was associated with high mortality while on the 
waiting list, and one-third of the patients who received a heart transplant died before hospital discharge. 
Overall, survival to hospital discharge of this population was 47%. In this context, other forms of temporary 
MCS are often considered for children awaiting heart transplantation.73 While bridging to transplantation 
represents a different clinical challenge than PC-ECMO, these studies may lead to innovative techniques for 















Limitations of the Review 
Pediatric PC-ECMO, particularly in the setting of CHD, is a technically challenging but potentially 
life-saving mode of support. There is limited evidence to inform clinical practice. We acknowledge several 
limitations to the current systematic review that are inherent to retrospective, observational studies. 
Indeed, most of the studies assembled here are single-center case series reports, precluding statistical 
analyses and lacking the power to detect some clinically significant differences in outcome. Secondly, the 
analyses were seldom adjusted for underlying confounders, such as duration of ECMO, cannulation strategy 
(peripheral vs central), cannula types and ECMO weaning protocols. Finally, although studies with large 
data sets coming from clinical registries (STS, ELSO, OPTN and PHIS) are discussed in the text, they were not 
included in the tables. 20, 21, 36, 38, 74   
 
Conclusion 
V-A ECMO is the optimal support technique in children with CHD and post-cardiotomy shock. ECMO 
facilitates augmented cardiac output and respiratory gas exchange to improve the metabolic status of both 
preoperative and post-cardiotomy patients. Although PC-ECMO can improve survival of this vulnerable 
population, mortality and morbidity remain high. Complications related to bleeding, thrombosis, and 
infections increase mortality and are major areas for improvement. Neurological injury and 
neurodevelopmental impairment are common in pediatric patients post PC-ECMO and reflect the severity 
of critical illness, complexity of cardiac surgery and complications of ECMO support. Bridging to cardiac 
transplantation can be successful if PC-ECMO does not lead to cardiac recovery, but the availability of 
organs and waiting list duration are ultimately factors in survival. The paucity of standardized care 
processes, informed patient selection, optimal timing of ECMO deployment, anticoagulation strategies or 
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Figure 1. Post-cardiotomy ECMO approaches for cannulation: central cannulation (right atrium and 

















Figure 2. Post-cardiotomy ECMO approaches for cannulation: central cannulation (right atrium and 


































TABLE 1. BASELINE CHARACTERISTICS  
Authorreference –                   











Anomalies, %: with normal segmental connections (1); of the 
atrioventricular valves (2); of the arterial valves and outflow tracts (3); 
with abnormal segmental connections (4); of the great vessels (5); of the 
coronary arteries (6); HTx (7); combined surgery (8); other (9). 
1 2  3  4  5  6  7  8  9  
Klein17 – 1990 
36* 
(NA) 
12.5%** 7.15 2.41 
13.6 months 
(1 day-7 years) 
47.2 2.8 11.1 2.8 2.8 5.6 NA 25.0 2.8 









17% 0 67 0 0 0 17 0 0 




15  7 months 
(0.75-72) 
54.5 NA 18.2 9.1 NA 9.1 NA 9.1 






28.6 months 13.8 3.1 21.5 26.2 7.7 4.6 7.7 6.2 9.2 





(2.9 – 12) 
12.5 months 
(0 day-6 years) 
4.2 8.3 8.3 NA 8.3 4.2 NA 50.0 16.7 
Dalton13 - 1993  
25 PC, 






8  7 
(2.5-35) 
17  23 months 
(2 weeks -7 
years) 
11*** 1 10 5 2 1 2 NA 2 
Black78 - 1995  
PC 25, 
6 no PC (11/14) 
NA 
6.13 ± 1.75† 
 
















Walters29 - 1995  73 
(44/29) 
1.6% 5.6 (median) 7.2 months 
(median) 
19.7 NA 13.6 7.6 7.6 NA 51.5 NA 
Kulik50 - 1996  
64 
(NA) 
NA 7.28±5.0  
14 ± 20.2 
months  
NA 2.4 24.4 14.6 7.3 4.9 2.4 7.3 36.6 






7.2 months (2 
weeks–3 years) 
44.4 0 11.1 22.2 22.2 0 0 0 11.1 







89 days  
 (median, 19 
days) 
7*** 3 9 7 9 1 NA 11 






NA 8 20 20 4 2 NA 46 
Pizarro68 – 2001 12  
(NA) 
NA 2.6  
(1.4-3.8)  
 
3.9 days (1-14) 0 0 0 0 0 0 0 100 0 







NA 8.1 4.1 8.1 NA 2.7 35.1 27.0    NA 









4.9 11.1 25.9 34.6 9.9 4.9 4.9 NA 3.7 






1 day – 17 
years, 4 months 
Univentricular repairs 7 (7.7%) 
Biventricular repairs 58 (64.4%) 
6.6 






4.7 months  
(1 day–42 yrs) 


























Ghez81 - 2005  15§
 
(NA) 
3.2% NA 4.97 ±7 years 6.7 NA 13.3 20.0 NA 6.7 26.7 26.7 
Mahle71 - 2005  32 NA NA 
2.0 months 
(4 days – 5.1 
years) 
0 6.3 6.3 9.4 12.5 6.3 3.1 0 46.9 










NA 34.6 11.5 NA 30.8 23.1 













15% 3.1±0.1 8.0±2.3 days     
SVP:100
% 
    










































NA 3.57 ± 1.7 7.5 ± 2.7 days 
HLHS 66,6% 
SVP: 33.3% 









1.6 3.1 12.5 17.2 10.9 NA 1.6 53.1 












































NA 2.8 2.8 5.6 2.7 NA 86.1 NA 









    
SVP: 
100% 
   
 










12.5 8.9 16.0 16.1 12.5 3.6 NA 3.6 
19.7+ 
7.1 NS 
























*  Additionally, 3 patients were supported with ECMO before surgery; 
** including 39 patients; 
*** multiple combinations per patient; 
† data reported for survivors only; 
‡ all patients in Cardiac Intensive Care Unit;  










































































§ 15 patients with 19 ECMO devices implanted (16 veno-arterial, 2 veno-venous, 1 x Biventricular Support); 
¶ Extracorporeal cardiopulmonary resuscitation (ECPR) in 41 postcardiotomy cases; 
BVP, biventricular pathology; ECMO, extracorporeal membrane oxygenation; HLHS, hypoplastic left heart syndrome; HTx, heart transplantation; IQR, 
















TABLE 2. ECMO IMPLANT INDICATION, IMPLANT LOCATION, AND IMPLANT ACCESS. 
Study 
Indications for ECMO 
implant, n (%) 
ECMO implant location, n (%) ECMO implant access, n (%) ECMO venting, n (%) 
Klein17 - 1990 
BVF 13 (36%) 
RVF 5 (14%) 
LVF 12 (33%) 
PVRC 6 (17%) 
OR 9 (25%) 
ICU 27 (75%) 
Neck 30 (83%) 
Chest 6 (17%) 
NA 
Ferrazzi75 - 1991 
LVF 1 (16.6%) 
RVF 4 (66.6%) 
BVF 1 (16.6) 
OR 2 (33%) 
ICU 4 (66%) 
Chest 6 (100%) NA 
del Nido76 - 1992  
Cardiac arrest 9 (82%) 
Not specified 2 (18%) 
NA 
Neck 1 (9%) 
Chest 10 (91%) 
3** (27%) 
Raithel77 - 1992  
Failure to wean from CPB 
20 (31%) 
Cardiac failure 45 (69%) 
OR 22 (34%) 
ICU 43  (66%) 
Chest 59 (91%) 
Femoral 6 (9%) 
LA vent 11 (17%) 
LV vent 4 (6%) 
Ziomek19 - 1992 
Ventricular failure 17 
(71%) 
Pulmonary hypertension 6 
(25%) 
OR 17 (71%) 
ICU 7 (29%) 
Neck 9 (38%) 
Chest 15 (62%) 













Hypoxemia 1 (4%) 
Dalton13 - 1993  
BVF + arrest 4 (15%) 
BVF 8 (30%) 
RVF 3 (11%) 
LVF 2 (7%) 
Cardiac arrest 9 (33%) 
Arrhythmia 1 (4%) 
NA 
Neck 5 (19%) 
Chest 22 (81%) 
LA vent 2 *** (7%) 
Black78 - 1995  
Myocardial failure 21 
(84%) 
Respiratory failure 3 (12%) 
Cardiac arrest 1 (4%) 
NA 
Chest 28 (90%) 
Femoral 3 (10%)† NA 
Walters29 - 1995  
Arrhythmia 1 (1.5%) 
Cardiac arrest 4 (6.1%) 
Low cardiac output 61 
(92.4%) 
No spontaneous electrical 
activity 1 (1.5%) 
Pulmonary artery 
hypertension 14 (21.2%) 
NA 
Neck 48 (73%) 














Kulik50 - 1996  
Ventricular dysfunction 26 
(41%) 
Pulmonary failure 13 
(20%) 
Pulmonary hypertension 7 
(11%) 
Combination 10 (16%) 
Cause of hemodynamic 
instability unknown 8 
(13%) 
NA 
Neck 37 (58%) 
Chest 20 (31%) 
Femoral 2 (3%) 
Multiple 5 (8%) 
LA vent (19%) 




Cardiac arrest (11%) 
OR 7 (78%) 
ICU 2 (22%) 
Chest 9 (100%) 0% 
Jaggers79 - 2000  
Low cardiac output 17 
(49%) 
Failure to wean from CPB 
10 (29%) 
Cardiac arrest 5 (14%) 
Arrhythmia 3 (9%) 
OR 15 (43%) 
ICU 20 (57%) 













Pulmonary Hypertension 2 
(6%) 
Hypoxia 1 (3%) 
Biventricular dysfunction 1 
(3%) 
Aharon80 - 2001  
Failure to wean from CPB 
22 (44%) 
Low cardiac output 11 
(22%) 
Pulmonary hypertension 7 
(14%) 
Cardiac arrest 10 (20%) 
OR 23 (46%) 
ICU 27 (54%) 
Neck 1 (2%) 
Chest 49 (98%) NA 
Pizarro68 - 2001 
Low cardiac output 6 
(50%) 
Cardiac arrest 2 (16.6%) 




circulation 1 (8.3%) 
Supraventricular 
OR 9 (75%) 
ICU 3 (25%) 













tachycardia 1 (8.3%) 
Kolovos18 - 2003 
Ventricular failure 51 
(69%) 
Respiratory failure 9 (12%) 
Pulmonary hypertension 4 
(5%) 
Multiple indications (not 
specified) 6 (8%) 
Shunt occlusion 4 (5%) 
NA 
Neck 26 (35%) 
Chest 47 (64%) 
Groin 1 (1%) 
LA vent 12 (16%) 
Atrial septostomy 1 (1%) 
Chaturvedi33 - 2004 
Failure to wean from CPB 
Low cardiac output 
No data available 
OR 47 (58%) 
ICU 34 (42%) 
Neck 5 (6%) 
Chest 76 (94%) NA 
Chow51 - 2004 
Myocarditis 10 (11%) 
Cardiomyopathy 9 (10%) 
Congenital Heart Disease 
71 (79%) 
NA NA NA 
Morris26 - 2004 
Cardiac arrest 













Low cardiac output 
Huang34 - 2005  
Failure to wean from CPB 
46 (67%) 
Low cardiac output 11 
(16%) 
Cardiac arrest 11 (16%) 
OR 46 (67%) 
ICU 22 (33%) 
Chest 66 (97%) 
Femoral 2 (3%) 
LA vent 12 (18%) 
Ghez81 - 2005  
Hemodynamic failure 12 
(63%) 
Respiratory failure 2 (11%) 
Mixed failure 5 (8%) 
OR 4 (27%) 
ICU 11 (73%) 
Neck 4 (21%) 
Chest 11 (58%) 
Femoral 4‡ (21%) 
NA 
Mahle71 - 2005  
Cardiopulmonary arrest 18 
(56%) 
Failure to wean from CPB 
11 (34%) 
Postoperative LCOS 2 (6%) 
Pulmonary hypertension 1 
(3%) 













Baslaim25 - 2006 
Ventricular failure 17 
(65%) 
Respiratory failure 6 (23%) 
Pulmonary hypertension 1 
(4%)  
 Allergic reaction to blood 
products 1 (4%) 
 Postoperative distal 
pulmonary artery stenting 
1 (4%) 
OR (not specified) 
ICU (not specified) 
Chest 26 (100%) NA 
Thourani28 - 2006 
Cardiomyopathy-
myocarditis 8 (30%) 
Systemic-to-pulmonary 
artery shunt dependent 
single ventricle 12 (44%) 
Postcardiotomy for 
biventricular repair 6 
(22%) 
Arrhythmias 1 (4%) 
NA NA NA 
Allan41 - 2008 
Myocardial failure 22 
(50%) 













Cardiac arrest 4 (9.1%) 
Tamponade 2 (4.5%) 
Pulmonary hypertension 1 
(2.3%)  




Alsoufi42 - 2009 
Failure to wean from CPB 
83 (46%) 
Low cardiac output 97 
(54%) 
Cardiac arrest 48 (27%) 
OR 83 (46%) 
ICU 92 (51%) 
Catherization laboratory 5 (3%) 
Neck 12 (6%) 
Chest 168 (94%) 
NA 
Delmo Walter82 - 
2010 
Cardiac Arrest 27 (100%) NA NA LV vent 5 (19%) 
Polimenakos27 - 
2011 
Cardiac arrest 17 (81%) 
Respiratory failure 
followed by cardiac arrest 
4 (19%) 
NA NA NA 
Bhat35 - 2013 
Failure to wean from CPB 
39 (61%) 













Low cardiac output 9 
(14%) 
Cardiac arrest 16 (25%) 
ICU 25 (39%) 
Sasson83 - 2013 
Failure to wean from CPB 
53 (83%) 
Cardiac arrest 9 (17%) 
OR 53 (83%) 
ICU 9 (17%) 
Neck 2 (3%) 
Chest 60 (97%) 
NA 
Agarwal16 - 2014  
Failure to wean from CPB 
50 (42%) 
Low cardiac output 25 
(21%) 
Cardiac arrest 34 (29%) 
Other (including 
arrhythmia, respiratory 
failure and pulmonary 
hypertension) 10 (8%) 
OR 58  (49%) 
ICU 61 (51%) 
NA NA 
Alsoufi43 - 2014  
Failure to wean from CPB 
34 (34%) 
Low cardiac output 29 
(29%) 
Cardiac arrest 37 (37%) 
OR 34 (34%) 














Sasaki37 - 2014 
Failure to wean from CPB 
14 (39%) 
Low cardiac output 15 
(42%) 
Other (not specified) 7 
(19%) 
OR 18 (50%) 
ICU 18 (50%) 
Chest 36 (100%) NA 
Jolley 48 - 2014 
cardiac 90 (87%) 
ECPR 9, (9%)  
pulmonary 4 (4%). 
NA 
Chest 89 (86%) 
Neck 14 (103%)  
NA 
Miana84 - 2015  
Failure to wean from CPB 
56 (100%) 
OR 56 (100%) Chest 56 (100%) Interatrial vent LA vent (not specified) 
Gupta22 - 2015  NA NA NA NA 
Lou85 - 2015 
Failure to wean from CPB 
24 (25%) 
Low cardiac output 26 
(27%) 
Cardiac arrest 46 (48%) 
NA 
Chest 90 (94%) 
Peripheral (not specified) 3 (3%) 




Low cardiac output 16 
(17%) 
Failure to wean from CPB 
OR 42 (45%) 
ICU 51 (55%) 
Neck 13 (14%) 















Pulmonary hypertension 2 
(2%) 
Combined cardiac and 
respiratory failure 26 
(28%) 
Respiratory failure 2 (2%) 
Shunt occlusion 3 (3%) 
Aydin11 – 2016 
Respiratory failure 59 
(63%)  
Cardiac failure 30 (32%) 
NA 
Neck 57 (64%) 
Chest 24 (27%) 
Femoral 10 (11%) 
NA 
Howard46-2016 
Cardiac arrest 39 (46%) 
Failure to wean from CPB 
21 (25%) 
LCOS 18 (21%) 
Hypoxemia 6 (7%) 
NA Chest 82 (98%) NA 
ElMahrouk86 - 2017  
Ventricular dysfunction 59 
(52%) 
Pulmonary Failure 34 
(30%) 
OR 88 (78%) 














Cardiac arrest 10 (9%) 
Pulmonary hypertension 7 
(6%) 
Other 3 (3%)* 
Mistry87 - 2018 
Cardiomyopathy 28 (41%) 
Cardiorespiratory failure 
28 (41%) 
Congenital heart disease 9 
(13%) 
Posttransplant rejection 5 
(7.4%) 
NA NA 16 (23.5%) 
*Arrhythmia, allergic reaction to blood products, and Fontan circuit thrombus. 
**Vent type not specified. 
*** Data on venting was only given for 2 patients. 
†No data on 25 PC patients 
‡15 patients, 19 ECLS runs 
BVF; biventricular failure, CPB, cardiopulmonary bypass; ECLS, extracorporeal life support; ECPR, extracorporeal cardiopulmonary resuscitation; ICU, intensive 
care unit; LA, left atrial; LCOS, low cardiac output syndrome; LV, left ventricular; LVF; left ventricular failure; NA, not available; OR, operating room; PC; post-













TABLE 3. DURATION OF ECMO SUPPORT, WEANING RATE, IN-HOSPITAL SURVIVAL, 1-YEAR SURVIVAL AND PREDICTORS OF IN-
HOSPITAL MORTALITY. 
Study 
Duration of ECMO, in 













Total: 105 ± 46 hours  
Survivors: 110 ± 27 hours 
(mean ± SD) 




126±47 hours (range: 67-173 
hours) 
3 (50%) 2 (33%) NA NA 
del Nido
76








Survivors: 87.9 hours, 45-
197.5 hours (mean + range) 




96 hours, 17-198 hours 
(mean + range) 
16 (75%) 13 (54%) NA Sepsis 
Dalton
13
 - 1993 113 ± 62 hours (mean ± SD) 14 (67%) 9 (43%) 7 (33%) Longer CPB time and shorter time on ECMO 
Black
78
 - 1995 5.7 days (mean) 10 (40%) 10 (40%) 10 (40%) NA 
Walters
29
 - 1995 115 ± 6 hours (mean ± SD) 44 (67%) 38 (58%) NA 
Longer CPB time, patients who couldn’t be weaned from CPB, 
Elevated BUN 48 h after ECMO cannulation, Elevated creatinine 
48 h after ECMO cannulation, Need of RBC’s on ECMO, Need 
of plasma on ECMO  Creatinine 48 h after ECMO decannulation 
and average right atrial pressure 8 h after ECMO decannulation 
Kulik
50



















5.6 days (median 5 days, 
range 0.7-16 days) 
NA 21 (61%) 17 (49%) 
Longer time on ECMO, development of renal failure, shunt left 




Survivors: 89 hours (mean) 
(range 20-192 hours) 
30 (60%) 25 (50%) 23 (45%) 
Renal failure requiring hemodialysis, ECMO duration >72 hours, 




67 hours (median 48 hours) 
range (24-192 hours) 




127 hours (median) (IQR 73-
209 hours) 
50 (68%) 37 (50%) NA 
CPR during ECMO cannulation, Renal failure/dialysis, single 




144 hours (median) (IQR 70-
226 hours) 
47 (58%) 40 (49%) 33 (41%) 
Circuit problems, renal failure/dialysis, residual cardiac lesions, 
ECMO duration, blood product transfusion and cross clamp time 
Chow 
51 
- 2004 90 hours (median) 6-394 
hours 







Survivors: 94.5 (median) 
(range 7 hours -15 days) 




Survivors: 75.3 hours 
(median) (range 23-234 
hours) 




























Survivors: 74.5 hours (mean) 
(range 12-189 hours) 












 -2007 Survivors 56±15 hours 
Non survivors 160±23 







Survivors: 3 days (median) 
(range 2.8-4.2 days) 
109 (61%) 68 (38%) NA 
Duration of ECMO, repeat ECMO, bleeding complications, 




4.97 ± 0.68 days (mean ± 
SD) 




7 days (median) (IQR 4-21 
days) 




Total: 164 hours (median) 
(IQR 95-231) 
Survivors: 134 hours (IQR 
95-160 hours)
33 (52%) 18 (28.1%) NA 




 - 2013 
Total: 4 days (median) 
(range 1-13 days) 
Survivors: 3 days (range 1-
13 days) 




4 days (median) (IQR 2-7 
days) 
75 (63%) 49 (41%) NA NA 
Alsoufi43 - 2014 Total: 4 days (median) (IQR 
3-6 days)
Survivors: 3 days (IQR 2-5
62 (62%) 37 (37%) NA 
Renal failure requiring dialysis, maximum creatinine, bleeding 
requiring re-exploration, ECMO duration, hours to lactate 













days) lactate, maximum bilirubin, Sepsis 
Sasaki
37
 - 2014 4.9 ± 4.2 days (mean ± SD) 21 (58%) 17 (47%) NA 
Univentricular anatomy, younger age, longer ECMO duration, 




survivors 88 hours (48-132) 
non survivors 136 hours (73-
267) 
68 (66%) 42 (41%) NA 
inotrope requirement, longer duration of ECMO support, 
combined cardiopulmonary indication 




182.2 ± 117 hours (mean ± 
SD) 
26 (46.4%) 11 (19.6%) NA NA 
Gupta
22
 - 2015 





NA Longer ECMO duration 
Lou
85
 - 2015 
Group 1 (ECMO without 
therapeutic hypothermia): 83 
hours (median) (range 26-
332 hours) 
Group 2 (ECMO with 
therapeutic hypothermia): 
106 hours (median) (range 
24-367 hours)
77 (80.2%) 55 (57.3%) NA NA 
Sznycer-Taub
23
 - 2016 
Total: 5 days (median) (IQR 
3-7 days)
30 day survivors:
4 days (IQR 3-6 days)
NA 46 (49%) NA 





survuvors:  88.5 hours(57-
116) 
non survivors:  183 hours 
(71-288) 
NA 46 (48%) NA 
The duration of intubation, partial pressure carbon dioxide, mean 
airway pressure, and renal injury 
Howard
46
-2016 7.5 (3-11) days NA 42 (50%) 34 (40%) 





4 days (median) (range 1-14 
days)  















 - 2018 126.97 hours (78.89-216.64) NA 48 (70.6%) 
48 
(69.2%)* 
Low body weight, serum lactate and creatinine, prior cardiac 
surgery, inotropes use. 
*3 patients lost to follow-up 
** mean follow-up 4.5 years 
BUN, blood urea nitrogen;  CPB, cardiopulmonary bypass;   CPR, cardiopulmonary resuscitation; DIC,  disseminated intravascular coagulation; ECMO, extracorporeal 
membrane oxygenation; h, hours;  HTx, heart transplantation;  IQR, interquartile range; OR, operating room;  NA, not available; PaO2, partial pressure of oxygen;   


































Klein17 - 1990 17 (47%) NA NA NA NA NA 
Ferrazzi75 - 1991 6 (100%) NA NA 3 (50%) 1 (17%) NA 
del Nido76 - 1992 1 (9%) NA NA 1 (9%) 3 (27%) NA 
Raithel77 - 1992 44 (68%) 7 (11%) NA 20 (31%) 18 (28%) 7 (11%) 
Ziomek19 - 1992 NA 3 (13%) NA 8 (33%) 1 (4%) 4 (17%) 
Dalton13 - 1993 6 (22%) NA NA 3 (11%) 6 (22%) NA 
Walters29 - 1995 5 (13%) NA 2 (5%) 4 (10%) 9 (24%) 3 (8%) 
Kulik50 - 1996 28 (44%) NA 
18 
(28%) 
12 (19%) 29 (45%) 28 (44%) 
Langley67 - 1998 4 (44%) NA NA 5 (56%) 1 (11%) 7 (78%) 
Jaggers79 - 2000 15 (35%) NA NA 9 (26%) 18 (51%) 9 (26%) 
Aharon80 - 2001 NA NA NA 7 (14%) NA 4 (8%) 
Pizarro68 - 2001 2 (17%) 1 (8%) NA 5 (42%) 3 (25%) 5 (42%) 
Kolovos18 - 2003 NA NA NA 11 (15%) 16 (22%) 26 (35%) 
Chaturvedi33 - 2004 51 (63%) 22 (27%) NA 22 (27%) NA 22 (27%) 
Chow51 - 2004 NA NA NA NA 20 (22%) NA 














Huang34 - 2005 34 (50%) NA NA NA NA 47 (69%) 
Ghez81 - 2005 NA NA NA 2 (13%) 0 (0%) 6 (40%) 
Mahle71 - 2005 NA 1 (3.1%) NA 1 (3.1%) 7 (21.9%) NA 
Baslaim25 - 2006 17 (65%) NA NA 4 (15%) 5 (19%) 8 (31%) 




Alsoufi42 - 2009 100 (56%) 68 (38%) NA NA 32 (18%) 18 (10%) 
Polimenakos27 - 2011 NA NA NA 4 (19%) 9 (43%) 7 (33%) 
Bhat35 - 2013 NA NA NA NA NA 36 (56%) 
Agarwal16 - 2014 NA NA NA NA NA 41 (34%) 
Alsoufi43 2014 49 (49%) 9 (9%) NA 21 (21%) 17 (17%) 55 (56%) 
Sasaki37 - 2014 17 (47%) 7 (19%) NA 10 (28%) 10 (28%) 19 (53%) 
Jolley 48 - 2014 48 (46%) 46 (44%) 7 (6%) 12 (11%) 24 (23%) 34 (33%) 
Miana84 - 2015 19 (34%) NA NA NA 6 (11%) 5 (9%) 
Lou85 - 2015 29 (30%) 11 (11%) NA 40 (42%) 11 (11%) 51 (53%) 
Sznycer-Taub23 - 2016 NA NA NA NA 39 (42%) 35 (38%) 













Howard46 – 2016 32 (43%) 41 (49%) 
16 
(19%) 
NA 21 (25%) 16 (19%) 
ElMahrouk86 - 2017 78 (69%) NA NA 35 (31%) 18 (16%) 41 (36%) 
*only data for survivors was reported
Studies that did not report complications 28, 40, 78, 82, 83, 87have been excluded from this table. 
CNS, central nervous system; ECMO, extracorporeal membrane oxygenation; NA, not available. 
